B-MS in immuno-oncology collaboration with UK's PsiOxus

1 July 2016

US drug maker Bristol-Myers Squibb (NYSE: BMY) has announced an exclusive clinical collaboration with England’s immuno-oncology company PsiOxus Therapeutics, it has been announced.

The partnership will see the two companies evaluate the safety, tolerability and efficacy of PsiOxus’ enadenotucirev in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) in a range of tumor types in late-stage cancer patients.

Enadenotucirev, an oncolytic adenovirus therapeutic, is designed to have immune stimulating effects while Opdivo, an immune-oncology (I-O) agent, is designed to alleviate immune suppression.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK